2018 American Transplant Congress
Association between Everolimus Trough Levels, Onset of Related Adverse Events, and Treatment Discontinuation after Liver Transplantation: 24-Month Results from the H2304 Study
Purpose: Evaluation of mammalian target of rapamycin inhibitor (mTORi)-related adverse events (AEs) and drug trough levels (C0) at onset may aid their management in liver…2018 American Transplant Congress
Greater Susceptibility for Metabolic Syndrome in Pediatric Transplant Recipients – A Case-Control Study
Introduction. Metabolic syndrome not only contributes to an increased risk for cardiovascular sequelae but is also associated with impaired graft function and lower graft survival…2018 American Transplant Congress
Simplified Once-Daily Immunosuppressive Regimen for Stable Kidney Recipients
Background. Many immunosuppressive drugs are prescribed as twice-daily dosing. Simplified once-daily dosing of the entire drug regimen can improve treatment satisfaction for patients. We examined…2018 American Transplant Congress
Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation
Mycophenolate mofetil (MMF) is generally administered as a fixed dose. Studies have shown a relationship between MPA exposure (MPAAUC) but no data evaluates this relationship…2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…2018 American Transplant Congress
Clinical Outcomes of Late Conversion to Once-Daily Tacrolimus after Liver Transplant
BackgroundSince a once-daily tacrolimus (TAC-OD) has been introduced in the field of transplantation, many studies reported advantages of the new drug, such as the better…2018 American Transplant Congress
Persistence and Homing of Autologous Donor-Reactive Ex-Vivo Expanded Regulatory T Cells to Heart Allografts in Lymphodepleted Recipient Monkeys
Surgery, Starzl Transplantation Institute, Pittsburgh, PA.
Background:Infusion of ex vivo expanded regulatory T cells (Treg) is a promising therapy to prevent allograft rejection. Trafficking of Treg to allografts and secondary (2ry)…2018 American Transplant Congress
mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial
Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Heart/Kidney Transplantation
Virginia Commonwealth University, Richmond.
Introduction: There is no published data on the risks and benefits of Induction immunosuppression in simultaneous heart/kidney transplant (SHKT) patients.Methods: We analyzed all SHKT performed…2018 American Transplant Congress
Prevalence and Impact of CYP3A5 Genomic Variances on Clinical Outcomes among African-American Kidney Transplant Recipients
1Vidant Medical Center, Greenville, NC; 2East Carolina University, Greenville, NC.
Introduction: Kidney transplantation in African American (AA) recipients continues to demonstrate inferior outcomes when compared with other race/ethnicities. Contributing factors encompass differences in pharmacogenomics, and…
- « Previous Page
- 1
- …
- 80
- 81
- 82
- 83
- 84
- …
- 138
- Next Page »